FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200561103> ?p ?o ?g. }

• W4200561103 endingPage "64" @default.
• W4200561103 startingPage "45" @default.
• W4200561103 abstract "RELAY was a global, double-blind, placebo-controlled phase III study that demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus placebo plus erlotinib (PBO + ERL) in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) mutation-positive, metastatic non-small-cell lung cancer (NSCLC). This article provides an in-depth analysis of the safety profile of RAM + ERL versus PBO + ERL observed in RELAY. Eligible patients met these criteria: stage IV NSCLC; EGFR exon 19 deletion or exon 21 substitution (L858R) mutation; Eastern Cooperative Oncology Group performance status 0 or 1; and no central nervous system metastases. Patients were randomized (1:1) to receive erlotinib 150 mg/day orally plus either ramucirumab 10 mg/kg intravenously or matching placebo once every 2 weeks, until disease progression or unacceptable toxicity. The primary endpoint was PFS. Safety was evaluated based on reported treatment-emergent adverse events (AEs) and clinical laboratory assessments. The safety population comprised 446 patients (221 in RAM+ERL arm; 225 in PBO + ERL arm) who received at least one dose of study drug between January 2016 and February 2018. The overall incidence of grade ≥ 3 AEs was higher with RAM + ERL than with PBO + ERL, primarily driven by grade 3 hypertension. Grade ≥ 3 dermatitis acneiform and diarrhea were also reported more frequently in the RAM + ERL arm. The increased incidence of AEs with RAM + ERL was easily detected through routine monitoring and managed through dose adjustments and appropriate supportive care. This in-depth safety analysis from RELAY supports that RAM + ERL, irrespective of the increased incidence of AEs, does not affect a patient’s ability to benefit from treatment. NCT02411448." @default.
• W4200561103 created "2021-12-31" @default.
• W4200561103 creator A5001428569 @default.
• W4200561103 creator A5013585698 @default.
• W4200561103 creator A5024261346 @default.
• W4200561103 creator A5027922287 @default.
• W4200561103 creator A5029670099 @default.
• W4200561103 creator A5031519214 @default.
• W4200561103 creator A5044399684 @default.
• W4200561103 creator A5046728958 @default.
• W4200561103 creator A5048965137 @default.
• W4200561103 creator A5051707942 @default.
• W4200561103 creator A5060287300 @default.
• W4200561103 creator A5069589468 @default.
• W4200561103 creator A5072452238 @default.
• W4200561103 date "2021-12-20" @default.
• W4200561103 modified "2023-10-10" @default.
• W4200561103 title "RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability" @default.
• W4200561103 cites W1828082159 @default.
• W4200561103 cites W1896254854 @default.
• W4200561103 cites W1971837077 @default.
• W4200561103 cites W2064227792 @default.
• W4200561103 cites W2085791471 @default.
• W4200561103 cites W2104759721 @default.
• W4200561103 cites W2111237964 @default.
• W4200561103 cites W2121847974 @default.
• W4200561103 cites W2123629654 @default.
• W4200561103 cites W2136601558 @default.
• W4200561103 cites W2140980839 @default.
• W4200561103 cites W2755607580 @default.
• W4200561103 cites W2797457733 @default.
• W4200561103 cites W2907814135 @default.
• W4200561103 cites W2910126224 @default.
• W4200561103 cites W2921434986 @default.
• W4200561103 cites W2933432838 @default.
• W4200561103 cites W2937223370 @default.
• W4200561103 cites W2968754080 @default.
• W4200561103 cites W2970658653 @default.
• W4200561103 cites W2978677918 @default.
• W4200561103 cites W3048845626 @default.
• W4200561103 cites W3087151336 @default.
• W4200561103 cites W3088761437 @default.
• W4200561103 cites W3093697047 @default.
• W4200561103 cites W3156170207 @default.
• W4200561103 cites W3191778845 @default.
• W4200561103 doi "https://doi.org/10.1007/s40264-021-01127-2" @default.
• W4200561103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34928484" @default.
• W4200561103 hasPublicationYear "2021" @default.
• W4200561103 type Work @default.
• W4200561103 citedByCount "6" @default.
• W4200561103 countsByYear W42005611032022 @default.
• W4200561103 countsByYear W42005611032023 @default.
• W4200561103 crossrefType "journal-article" @default.
• W4200561103 hasAuthorship W4200561103A5001428569 @default.
• W4200561103 hasAuthorship W4200561103A5013585698 @default.
• W4200561103 hasAuthorship W4200561103A5024261346 @default.
• W4200561103 hasAuthorship W4200561103A5027922287 @default.
• W4200561103 hasAuthorship W4200561103A5029670099 @default.
• W4200561103 hasAuthorship W4200561103A5031519214 @default.
• W4200561103 hasAuthorship W4200561103A5044399684 @default.
• W4200561103 hasAuthorship W4200561103A5046728958 @default.
• W4200561103 hasAuthorship W4200561103A5048965137 @default.
• W4200561103 hasAuthorship W4200561103A5051707942 @default.
• W4200561103 hasAuthorship W4200561103A5060287300 @default.
• W4200561103 hasAuthorship W4200561103A5069589468 @default.
• W4200561103 hasAuthorship W4200561103A5072452238 @default.
• W4200561103 hasBestOaLocation W42005611031 @default.
• W4200561103 hasConcept C121608353 @default.
• W4200561103 hasConcept C126322002 @default.
• W4200561103 hasConcept C142724271 @default.
• W4200561103 hasConcept C143998085 @default.
• W4200561103 hasConcept C197934379 @default.
• W4200561103 hasConcept C203092338 @default.
• W4200561103 hasConcept C204787440 @default.
• W4200561103 hasConcept C27081682 @default.
• W4200561103 hasConcept C2776256026 @default.
• W4200561103 hasConcept C2777930144 @default.
• W4200561103 hasConcept C2778087573 @default.
• W4200561103 hasConcept C2779438470 @default.
• W4200561103 hasConcept C2779551604 @default.
• W4200561103 hasConcept C2780580887 @default.
• W4200561103 hasConcept C2908647359 @default.
• W4200561103 hasConcept C535046627 @default.
• W4200561103 hasConcept C71924100 @default.
• W4200561103 hasConcept C90924648 @default.
• W4200561103 hasConcept C99454951 @default.
• W4200561103 hasConceptScore W4200561103C121608353 @default.
• W4200561103 hasConceptScore W4200561103C126322002 @default.
• W4200561103 hasConceptScore W4200561103C142724271 @default.
• W4200561103 hasConceptScore W4200561103C143998085 @default.
• W4200561103 hasConceptScore W4200561103C197934379 @default.
• W4200561103 hasConceptScore W4200561103C203092338 @default.
• W4200561103 hasConceptScore W4200561103C204787440 @default.
• W4200561103 hasConceptScore W4200561103C27081682 @default.
• W4200561103 hasConceptScore W4200561103C2776256026 @default.
• W4200561103 hasConceptScore W4200561103C2777930144 @default.
• W4200561103 hasConceptScore W4200561103C2778087573 @default.
• W4200561103 hasConceptScore W4200561103C2779438470 @default.

• next